Ingunn Holen
Ingunn Holen
Verified email at - Homepage
Cited by
Cited by
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ...
Breast Cancer Research 15, 1-37, 2013
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ...
Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001
Bone metastases
RE Coleman, J Brown, I Holen
Abeloff's clinical oncology, 809-830. e3, 2020
Tumour macrophages as potential targets of bisphosphonates
TL Rogers, I Holen
Journal of translational medicine 9, 1-17, 2011
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
I Holen, PI Croucher, FC Hamdy, CL Eaton
Cancer research 62 (6), 1619-1623, 2002
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
M Coscia, E Quaglino, M Iezzi, C Curcio, F Pantaleoni, C Riganti, I Holen, ...
Journal of cellular and molecular medicine 14 (12), 2803-2815, 2010
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
MC Winter, I Holen, RE Coleman
Cancer treatment reviews 34 (5), 453-475, 2008
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
PD Ottewell, H Mönkkönen, M Jones, DV Lefley, RE Coleman, I Holen
Journal of the National Cancer Institute 100 (16), 1167-1178, 2008
Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies
NS Wind, I Holen
International journal of breast cancer 2011 (1), 967419, 2011
In vivo models in breast cancer research: progress, challenges and future directions
I Holen, V Speirs, B Morrissey, K Blyth
Disease models & mechanisms 10 (4), 359-371, 2017
IL-1 drives breast cancer growth and bone metastasis in vivo
I Holen, DV Lefley, SE Francis, S Rennicks, S Bradbury, RE Coleman, ...
Oncotarget 7 (46), 75571, 2016
Sequence‐and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
HL Neville‐Webbe, A Rostami‐Hodjegan, CA Evans, RE Coleman, ...
International journal of cancer 113 (3), 364-371, 2005
Dependence of hepatocytic autophagy on intracellularly sequestered calcium.
PB Gordon, I Holen, M Fosse, JS Røtnes, PO Seglen
Journal of Biological Chemistry 268 (35), 26107-26112, 1993
Bone metastasis: mechanisms, therapies, and biomarkers
P Clézardin, R Coleman, M Puppo, P Ottewell, E Bonnelye, F Paycha, ...
Physiological reviews 101 (3), 797-855, 2021
Optimizing the yield and utility of circulating cell-free DNA from plasma and serum
X Xue, MD Teare, I Holen, YM Zhu, PJ Woll
Clinica chimica acta 404 (2), 100-104, 2009
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, RE Coleman, C Wilson, TJ Powles, P Clézardin, M Aapro, ...
Annals of Oncology 27 (3), 379-390, 2016
Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo
PD Ottewell, N Wang, HK Brown, KJ Reeves, CA Fowles, PI Croucher, ...
Clinical Cancer Research 20 (11), 2922-2932, 2014
Pathophysiological roles of osteoprotegerin (OPG)
P Reid, I Holen
European journal of cell biology 88 (1), 1-17, 2009
Metastasis and bone loss: advancing treatment and prevention
RE Coleman, A Lipton, GD Roodman, TA Guise, BF Boyce, AM Brufsky, ...
Cancer treatment reviews 36 (8), 615-620, 2010
Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?
I Holen, SS Cross, HL Neville-Webbe, NA Cross, SP Balasubramanian, ...
Breast cancer research and treatment 92, 207-215, 2005
The system can't perform the operation now. Try again later.
Articles 1–20